What is the half-life of Gonadorelin?

Gonadorelin has a half-life of 2-4 minutes (IV); ~10-40 minutes (SC), which is why it's typically administered 2-3 times per week (pulsatile protocols vary) for optimal therapeutic effect.

How do I reconstitute Gonadorelin?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Approved

Gonadorelin

Also known as: GnRH, LHRH, Factrel, Lutrelef, Gonadorelin Hydrochloride

Overview

Key Facts

Primary Goal: A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH)

A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). When administered in a pulsatile fashion, it stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, supporting natural testosterone and estrogen production. Half-Life 2-4 minutes (IV); ~10-40 minutes (SC) Typical Dose 50–200 mcg Frequency 2-3 times per week (pulsatile protocols vary) Cycle Length 4-12 weeks in hormone optimization protocols

Dosing Information

Half-Life

2-4 minutes (IV); ~10-40 minutes (SC)

Typical Dose

50–200 mcg

Frequency

2-3 times per week (pulsatile protocols vary)

Cycle Length

4-12 weeks in hormone optimization protocols

Administration Routes:

subcutaneousintravenous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Approved

Gonadorelin was FDA-approved under the brand names Factrel (for diagnostic use) and Lutrepulse (for pulsatile therapeutic use in hypothalamic amenorrhea). It is the gold-standard diagnostic agent for assessing pituitary GnRH responsiveness. In research and clinical practice, pulsatile gonadorelin has been used to restore fertility in patients with hypothalamic hypogonadism. It has gained renewed interest in the peptide community for maintaining endogenous hormone production alongside testosterone replacement therapy.